dextromethorphan + sitagliptin

Dextromethorphan + sitagliptin is an investigational pharmaceutical combination for the treatment of type 2 diabetes mellitus. Dextromethorphan, traditionally an antitussive (cough suppressant), has demonstrated beta-cell protective properties and may increase insulin production. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances endogenous insulin response by increasing incretin hormone levels. The combination has shown a greater reduction in blood glucose and a larger increase in early insulin secretion during oral glucose tolerance tests, compared to sitagliptin alone. Clinical studies report that the combination is well tolerated without serious adverse events or hypoglycemia in short-term trials. Long-term safety and efficacy remain under investigation[1][3][4].